Latest Market Segments News

Comms Group Limited announces a strategic $10 million acquisition of TasmaNet and select assets from Field Solutions Holdings, alongside a $7 million capital raise, targeting a proforma FY25 revenue of approximately $75 million.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Cash Converters International Limited reveals a strategic shift towards sustainable, lower-cost lending and expands its global footprint through targeted franchise acquisitions in Australia and the UK.

IODM Limited has secured a new revenue share agreement with Converain targeting Japan’s growing international education market, marking its fourth such deal globally.

Macquarie Group reported a 5% increase in net profit to A$3.7 billion for FY25, driven by strong asset management and banking results despite a dip in commodities. The group also extended its $2 billion share buyback and declared a solid final dividend.

Macquarie Bank Limited reported an 18% rise in net profit for FY2025, driven by growth in its retail banking segment despite margin pressures, while its commodities business faced subdued markets. The bank maintained strong capital ratios and advanced its risk and technology frameworks amid regulatory scrutiny.

Macquarie Group reported a 5% increase in full-year net profit to A$3.7 billion for FY25, driven by strong second-half growth and robust asset management performance. The company declared a final dividend of A$3.90 per share and extended its share buyback program.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed a significant five-year, A$20 million contract to implement its cloud-based Visage 7 imaging platform at University of Iowa Health Care, marking a major step in cloud adoption for healthcare IT.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

AdAlta Limited has announced a pro rata renounceable rights offer to raise approximately $1.29 million, aiming to fund its strategic pivot towards licensing CAR-T cell therapies through its subsidiary AdCella. The offer includes new shares and options, underpinned by key insiders and an underwriting agreement.

Forbidden Foods Limited has reported a remarkable 218% increase in April invoiced sales, driven by robust ecommerce growth and the recent integration of Oat Milk Goodness. The company is on track to surpass $4 million in annual sales, signaling strong momentum in the health and wellness FMCG sector.

Zimi Limited confirms $1.42 million in open orders with key distributor GSM Electrical, backed by shareholder approval for up to $6 million in future sales. The company also advances its commercial market ambitions through a new partnership with Zencontrol.